Estimating the impact of direct acting antiviral therapy on the prevalence of hepatitis C virus infection using phylogenetics.

ABSTRACT:

Introduction

Australia has provided unrestricted subsidized access to direct-acting antiviral (DAA) treatment for hepatitis C virus (HCV) infection since 2016. Epidemiological surveillance estimates suggest prevalence of chronic HCV infection has declined since 2016, but these estimates are not separated by genotype and may not capture 'hidden' infected populations, notably the most marginalized groups affected, including people who inject drugs and people in prison. This study used phylogenetics to assess whether epidemiological estimates of declining HCV prevalence in the prisons of New South Wales, Australia due to DAA scale up could be reproduced.

Method

Near-full-length 280 HCV consensus sequences (GT1a: n = 140, GT3a: n = 140) sampled between 2006 - 2019 from two priso

SUBMITTER: Sazzad HMS 

PROVIDER: S-EPMC11999633 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature